In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women’s Interagency HIV Study Combined Cohort
- 17 September 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Abstract
Background: Tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) is an objective drug concentration measure which is predictive of future viremia in virally-suppressed persons with HIV (PWH) on TFV-based antiretroviral therapy (ART). Viral load (VL):TFV-DP mismatch (suppressed VL despite low TFV-DP concentrations) may increase future viremia risk. Previously, Black race, male sex, and higher body mass index were associated with lower TFV-DP concentrations among PWH receiving tenofovir disoproxil fumarate (TDF). The aim of this study was to assess mismatch rates in PWH on tenofovir alafenamide (TAF). Methods: DBS samples were obtained from Multicenter AIDS Cohort Study/Women’s Interagency HIV Study Combined Cohort participants receiving TAF-based ART for ≥3 months. Associations between pre-specified covariates and pharmacologic virologic mismatch (plasma VL <200 copies/mL and intracellular TFV-DP concentrations <1800 fmol/punches), were evaluated using logistic regression. Results: DBS was measured in 627 PWH (63% female) and median [IQR] age 55 [47-61] years. TFV-DP for VL 200 copies/mL was 2,375 [1,493-3,340] and 264 [13-949] fmol/punches, respectively. Females experienced 39% mismatch. Higher estimated glomerular filtration rate (eGFR; +15 mL/minute/1.73 m2), weight (+15 kg), and lower self-reported adherence (<95%) were associated with higher mismatch odds: 1.77 (1.40-2.28), 1.32 (1.11-1.57), and 5.12 (2.16-12.90), respectively. Males experienced 27% mismatch. Higher eGFR, weight, Black race, and lower adherence were associated with higher mismatch odds: 1.75 (1.22-2.62), 1.66 (1.19-2.39), 7.53 (2.87-22.28), and 9.61 (2.17-51.95), respectively. Conclusions: Weight, eGFR, self-reported adherence and Black race in males were associated with mismatch. These characteristics should be considered when designing adherence interventions.Keywords
This publication has 24 references indexed in Scilit:
- Short Communication: Tenofovir Diphosphate in Dried Blood Spots As an Objective Measure of Adherence in HIV-Infected WomenAIDS Research and Human Retroviruses, 2015
- HIV therapy, metabolic and cardiovascular health are associated with glomerular hyperfiltration among men with and without HIV infectionAIDS, 2014
- Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse EventsPLOS ONE, 2013
- Assessing Antiretroviral Adherence via Electronic Drug Monitoring and Self-Report: An Examination of Key Methodological IssuesAIDS and Behavior, 2006
- Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical ManagementAIDS and Behavior, 2006
- The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the BenchClinical and Vaccine Immunology, 2005
- Psychosocial Risk Factors of HIV Morbidity and Mortality: Findings from the Multicenter AIDS Cohort Study (MACS)Journal of Clinical and Experimental Neuropsychology, 2003
- Adherence to Antiretroviral Therapy by Human Immunodeficiency Virus–Infected PatientsThe Journal of Infectious Diseases, 2002
- The Women's Interagency HIV Study. WIHS Collaborative Study Group.1998
- THE MULTICENTER AIDS COHORT STUDY: RATIONALE, ORGANIZATION, AND SELECTED CHARACTERISTICS OF THE PARTICIPANTSAmerican Journal of Epidemiology, 1987